August 23, 2016
BTG receives Health Canada approval for DC Bead LUMI™ First commercially available radiopaque drug-eluting bead in Canada that provides real-time visible confirmation of bead location during embolization for the treatment of tumours in patients with HCC and mCRC

Ottawa, Canada, 23 August 2016

BTG International Canada Inc., part of the global specialist healthcare company BTG (LSE:BTG), today announced that it has received approval from Health Canada for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead that can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma (HCC) and malignant colorectal cancer metastasized to the liver (mCRC).1

DC Bead LUMI™ is a next generation development of DC Bead® that enables real-time visible confirmation of bead location during embolization. This innovative new technology has the potential to provide interventional radiologists increased control, enabling real-time adjustments to optimize patient treatment. The lasting radiopacity of DC Bead LUMI™ also means it will also be visible in follow-up scans, allowing precise evaluation of the completeness of tumour treatment.2

Brad Pearson, Director, Commercial Operations at BTG International Canada Inc., commented:"DC Bead LUMI™ reinforces our leadership in embolization technology and our focus on bringing to market innovative products that better serve specialist physicians and their patients. We are excited by the potential to offer a new standard of care and look forward to providing DC Bead LUMI™ to Canadian physicians during the second half of 2016."

BTG anticipates securing regulatory clearances for additional radiopaque bead products in other markets worldwide.

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

About BTG Interventional Medicine

BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com.

For more information contact:
Canadian Media Inquiries:
Eileen Tobey, beSPEAK Communications Inc.
Eileen@bespeakcommunications.com
+1416 540 4047

International Inquiries:
Chris Sampson, Director of Corporate Communications
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

Investor Relations Inquiries:
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

References:
1. DC Bead LUMI™ Radiopaque Embolic Drug-Eluting Bead Canadian Instructions for Use V.1
2. Duran et al. Theranostics 6(1) 2016:28-39